PT1112075E - Composições para o tratamento da disfunção eréctil masculina - Google Patents
Composições para o tratamento da disfunção eréctil masculina Download PDFInfo
- Publication number
- PT1112075E PT1112075E PT99946977T PT99946977T PT1112075E PT 1112075 E PT1112075 E PT 1112075E PT 99946977 T PT99946977 T PT 99946977T PT 99946977 T PT99946977 T PT 99946977T PT 1112075 E PT1112075 E PT 1112075E
- Authority
- PT
- Portugal
- Prior art keywords
- alprostadil
- phentolamine
- composition
- buffer
- papaverine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 201000001881 impotence Diseases 0.000 title claims abstract description 32
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract description 70
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229960000711 alprostadil Drugs 0.000 claims abstract description 64
- 239000000872 buffer Substances 0.000 claims abstract description 62
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 48
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960003056 phentolamine mesylate Drugs 0.000 claims abstract description 36
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960003207 papaverine hydrochloride Drugs 0.000 claims abstract description 29
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 25
- 229930064664 L-arginine Natural products 0.000 claims abstract description 25
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 25
- 239000004471 Glycine Substances 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 54
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 42
- 229960001999 phentolamine Drugs 0.000 claims description 41
- 229960001789 papaverine Drugs 0.000 claims description 30
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 26
- 239000000758 substrate Substances 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 235000009697 arginine Nutrition 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 10
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 10
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 10
- 150000003180 prostaglandins Chemical class 0.000 claims description 10
- 239000000674 adrenergic antagonist Substances 0.000 claims description 9
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 7
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003310 sildenafil Drugs 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 9
- 239000007924 injection Substances 0.000 description 25
- 238000002347 injection Methods 0.000 description 25
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 210000003899 penis Anatomy 0.000 description 20
- 239000007926 intracavernous injection Substances 0.000 description 17
- 239000002550 vasoactive agent Substances 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000013543 active substance Substances 0.000 description 10
- 230000018052 penile erection Effects 0.000 description 10
- 230000004872 arterial blood pressure Effects 0.000 description 9
- ZKVLEFBKBNUQHK-UHFFFAOYSA-N helium;molecular nitrogen;molecular oxygen Chemical compound [He].N#N.O=O ZKVLEFBKBNUQHK-UHFFFAOYSA-N 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000001568 sexual effect Effects 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 235000019445 benzyl alcohol Nutrition 0.000 description 8
- 230000001856 erectile effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 5
- 230000002227 vasoactive effect Effects 0.000 description 5
- IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940015688 caverject Drugs 0.000 description 3
- 210000005226 corpus cavernosum Anatomy 0.000 description 3
- -1 hemihydrates Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004648 relaxation of smooth muscle Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940013191 edex Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000008288 physiological mechanism Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 201000011264 priapism Diseases 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- OGIYDFVHFQEFKQ-UHFFFAOYSA-N 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 OGIYDFVHFQEFKQ-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010034319 Penile swelling Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 description 1
- 229960003002 atipamezole Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/154,677 US6482426B1 (en) | 1998-09-17 | 1998-09-17 | Compositions for the treatment of male erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1112075E true PT1112075E (pt) | 2006-12-29 |
Family
ID=22552291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT99946977T PT1112075E (pt) | 1998-09-17 | 1999-09-17 | Composições para o tratamento da disfunção eréctil masculina |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US6482426B1 (enExample) |
| EP (1) | EP1112075B1 (enExample) |
| JP (1) | JP4721517B2 (enExample) |
| CN (1) | CN1338939B (enExample) |
| AT (1) | ATE338554T1 (enExample) |
| AU (1) | AU772922B2 (enExample) |
| CA (1) | CA2344435C (enExample) |
| DE (1) | DE69933128T2 (enExample) |
| DK (1) | DK1112075T3 (enExample) |
| ES (1) | ES2273509T3 (enExample) |
| PT (1) | PT1112075E (enExample) |
| WO (1) | WO2000015233A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905707B2 (en) * | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
| US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
| US6476037B1 (en) | 2000-03-23 | 2002-11-05 | The Regents Of The University Of California | L-arginine and phosphodiesterase (PDE) inhibitor synergism |
| CN1315504A (zh) * | 2000-03-24 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人磷酸核糖甘氨酰胺合成酶12和编码这种多肽的多核苷酸 |
| DK1280531T3 (da) * | 2000-05-12 | 2007-05-29 | Novalar Pharmaceuticals Inc | Formulering bestående af phentolaminmesylat og anvendelse heraf |
| GB2375303A (en) * | 2001-05-11 | 2002-11-13 | Medical Res Council | Method of inducing cervical ripening |
| DE10142418A1 (de) * | 2001-08-31 | 2003-04-03 | Molecular And Clinical Drug Re | Arzneimittel |
| AU2003247568B2 (en) * | 2002-06-20 | 2008-03-06 | Septodont Holding Sas | Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| US7037257B1 (en) * | 2002-08-22 | 2006-05-02 | Koenig J Frank | Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications |
| KR20040043996A (ko) * | 2002-11-20 | 2004-05-27 | 조나겐, 아이엔씨. | 남성 발기부전치료를 위한 개선된 조성물 |
| JP4615929B2 (ja) * | 2004-08-11 | 2011-01-19 | 久光製薬株式会社 | イオントフォレーシス装置 |
| US7608589B2 (en) * | 2005-07-25 | 2009-10-27 | Therimunex Pharmaceuticals, Inc. | Peptidyl diacylglycerides |
| US20090112197A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
| US7862598B2 (en) * | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US8642093B2 (en) * | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US20110190604A1 (en) * | 2006-12-22 | 2011-08-04 | Hyde Roderick A | Nitric oxide sensors and systems |
| US8221690B2 (en) * | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
| US20090110933A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices related to nitric oxide releasing materials |
| US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
| US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
| US8877508B2 (en) * | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
| US8349262B2 (en) * | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
| US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| US20090112193A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
| US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US20090259217A1 (en) * | 2008-04-09 | 2009-10-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems associated with delivery of one or more agents to an individual |
| US20090259214A1 (en) * | 2008-04-09 | 2009-10-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Agent delivery device |
| WO2010070617A1 (en) * | 2008-12-19 | 2010-06-24 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
| AU2010363656C1 (en) * | 2010-11-12 | 2015-07-30 | Colgate-Palmolive Company | Oral care product and methods of use and manufacture thereof |
| US8560453B2 (en) | 2011-06-30 | 2013-10-15 | Intel Corporation | Method and apparatus for dynamic, real-time ad insertion based on meta-data within a hardware based root of trust |
| US20130303566A1 (en) * | 2012-05-09 | 2013-11-14 | David W. Hill | Method for treating macular degeneration |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| WO2018220232A1 (en) * | 2017-06-02 | 2018-12-06 | Universite De Versailles-St Quentin En Yvelines | Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction |
| CN109820820B (zh) * | 2019-02-25 | 2021-12-21 | 浙江长典药物技术开发有限公司 | 一种前列地尔注射液及其制备方法 |
| CN110193011B (zh) * | 2019-06-19 | 2022-02-11 | 四川美大康华康药业有限公司 | 一种甲磺酸酚妥拉明注射液及其制备方法 |
| CN111789818B (zh) * | 2020-08-15 | 2022-02-22 | 山东北大高科华泰制药有限公司 | 注射用盐酸罂粟碱药物组合物及制备方法 |
| US12053479B2 (en) | 2020-10-22 | 2024-08-06 | Madera Pharm aceuticals, Inc. | Transdermal treatment for erectile dysfunction |
| CN113143868B (zh) * | 2021-03-03 | 2022-04-12 | 海南久常制药有限公司 | 一种注射用盐酸罂粟碱及其制备方法 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3943246A (en) | 1972-07-10 | 1976-03-09 | Sandoz Ltd. | Organic compounds |
| US4139617A (en) | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4746651A (en) * | 1983-11-01 | 1988-05-24 | Scripps Clinic And Research Foundation | Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives |
| US4530920A (en) | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
| US4885173A (en) | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
| US4863911A (en) | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US5059603A (en) | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
| WO1990015583A1 (fr) | 1989-06-16 | 1990-12-27 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Dispositif de traitement de la faiblesse sexuelle chez l'homme |
| FR2649613B1 (fr) | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
| US5079018A (en) | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
| US5236904A (en) | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
| US5270323A (en) | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5399581A (en) | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
| US5298261A (en) | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
| US5646181A (en) * | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
| US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| DK172203B1 (da) * | 1996-03-11 | 1998-01-05 | Gitte Bjeldbak | Elskovsmiddel, der virker seksuelt ophidsende på brugeren |
| PT996447E (pt) * | 1997-05-19 | 2006-12-29 | Zonagen Inc | Terapia combinada para moldular a resposta sexual humana |
| US20020068365A1 (en) * | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
| US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
-
1998
- 1998-09-17 US US09/154,677 patent/US6482426B1/en not_active Expired - Lifetime
-
1999
- 1999-09-17 PT PT99946977T patent/PT1112075E/pt unknown
- 1999-09-17 DK DK99946977T patent/DK1112075T3/da active
- 1999-09-17 ES ES99946977T patent/ES2273509T3/es not_active Expired - Lifetime
- 1999-09-17 EP EP99946977A patent/EP1112075B1/en not_active Expired - Lifetime
- 1999-09-17 AU AU59270/99A patent/AU772922B2/en not_active Ceased
- 1999-09-17 AT AT99946977T patent/ATE338554T1/de active
- 1999-09-17 CA CA2344435A patent/CA2344435C/en not_active Expired - Fee Related
- 1999-09-17 WO PCT/US1999/021513 patent/WO2000015233A1/en not_active Ceased
- 1999-09-17 DE DE69933128T patent/DE69933128T2/de not_active Expired - Lifetime
- 1999-09-17 CN CN998132926A patent/CN1338939B/zh not_active Expired - Fee Related
- 1999-09-17 JP JP2000569817A patent/JP4721517B2/ja not_active Expired - Fee Related
-
2000
- 2000-01-31 US US09/494,627 patent/US6696072B1/en not_active Expired - Lifetime
-
2003
- 2003-11-03 US US10/700,274 patent/US7776899B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002524520A (ja) | 2002-08-06 |
| JP4721517B2 (ja) | 2011-07-13 |
| US20040102475A1 (en) | 2004-05-27 |
| CN1338939A (zh) | 2002-03-06 |
| WO2000015233A1 (en) | 2000-03-23 |
| AU5927099A (en) | 2000-04-03 |
| CA2344435C (en) | 2010-02-16 |
| CN1338939B (zh) | 2012-07-04 |
| US7776899B2 (en) | 2010-08-17 |
| DE69933128T2 (de) | 2007-08-16 |
| EP1112075A1 (en) | 2001-07-04 |
| CA2344435A1 (en) | 2000-03-23 |
| ATE338554T1 (de) | 2006-09-15 |
| ES2273509T3 (es) | 2007-05-01 |
| DE69933128D1 (de) | 2006-10-19 |
| US6482426B1 (en) | 2002-11-19 |
| EP1112075B1 (en) | 2006-09-06 |
| US6696072B1 (en) | 2004-02-24 |
| DK1112075T3 (da) | 2006-12-27 |
| AU772922B2 (en) | 2004-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1112075E (pt) | Composições para o tratamento da disfunção eréctil masculina | |
| RU2373938C9 (ru) | Пиразилпиримидиноны для лечения импотенции | |
| US5583144A (en) | Methods for treating erectile impotence | |
| MXPA01012877A (es) | Administracion nasal de apomorfina. | |
| AU749703B2 (en) | Combination therapy for modulating the human sexual response | |
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| CA2391968A1 (en) | An improved pharmaceutical composition for treating male erectile dysfunction | |
| JP4175801B2 (ja) | 消炎鎮痛点眼剤 | |
| Lue et al. | Pharmacotherapy for erectile dysfunction | |
| JP2753972B2 (ja) | インポテンツの治療 | |
| CA2641819A1 (en) | Composition for promoting vascular smooth muscle relaxation | |
| JPH08259440A (ja) | 急性尿閉治療用脱アセチル化モキシシライト | |
| US20250064830A1 (en) | Transdermal treatment for erectile dysfunction | |
| KR20040043996A (ko) | 남성 발기부전치료를 위한 개선된 조성물 | |
| WO2002011729A1 (en) | Novel compositions and methods for treatment of male erectile dysfunction | |
| US20030207891A1 (en) | Combination therapy for modulating the human sexual response | |
| MXPA99010400A (en) | Combination therapy for modulating the human sexual response | |
| MXPA00004846A (es) | Formulaciones nasales de citrato de sildenafil. |